{"product_id":"global-ophthalmic-disease-therapeutics-market-size-study-forecast-by-drug-class-anti-inflammatory-anti-invectives-anti-vegf-and-others-by-dosage-form-solid-liquid-and-semisolid-by-disease-indication-glaucoma-dry-eye-disease-retinal-disease","title":"Global Ophthalmic Disease Therapeutics Market Size Study \u0026 Forecast, by Drug Class (Anti-inflammatory, Anti-invectives, Anti-VEGF and Others) by Dosage Form (Solid, Liquid and Semisolid), by Disease Indication (Glaucoma, Dry Eye Disease, Retinal Disease,","description":"\u003cp\u003eGlobal Ophthalmic Disease Therapeutics Market Size Study \u0026amp; Forecast, by Drug Class (Anti-inflammatory, Anti-invectives, Anti-VEGF and Others) by Dosage Form (Solid, Liquid and Semisolid), by Disease Indication (Glaucoma, Dry Eye Disease, Retinal Disease, Allergy \u0026amp; Infections and Others), by Distribution Channel (Hospital Pharmacies, Retail \u0026amp; Online Pharmacies) and Regional Analysis, 2022-2029\u003cbr\u003e\nGlobal Ophthalmic Disease Therapeutics Market is valued at approximately USD 31.54 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.4% over the forecast period 2022-2029. Drugs and therapies for treating various ocular ailments such as glaucoma, dry eye disease, retinal diseases, and others are included in ophthalmic disease therapeutics. The Ophthalmic Disease Therapeutics market is expanding because of factors such as the rising prevalence of ophthalmic conditions and increasing clinical trials and pipeline candidates for Innovative Drugs and Therapies.\u003c\/p\u003e\n\n\u003cp\u003eGlobally, the prevalence of ophthalmic diseases such as glaucoma, retinal diseases, dry eye disease, and others is on the rise which is catering for market growth. According to a 2020 article from the American Academy of Ophthalmology (AAO), 3.0 million Americans, of whom 2.7 million are 40 years of age or older, have glaucoma. According to the World Bank Group, the world’s old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. The increasing number of initiatives taken by various healthcare organizations, governmental entities, and industry actors, there is a greater awareness among the public about ocular disorders, the market demand for treatments for ocular diseases is anticipated to be boosted by factors such as growing healthcare costs and an increase in the number of ophthalmologists in both developed and developing nations. According to the Welsh Government's 2021 report, The number of ophthalmic practitioners in Wales climbed to 961 in March 2021 from 885 in March 2020.  However, the high cost of Ophthalmic Disease Therapeutics stifles market growth throughout the forecast period of 2022-2029.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Ophthalmic Disease Therapeutics  Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the increasing rates of diagnosis and treatment, as well as an increase in the prevalence of numerous ocular illnesses. Additionally, rising healthcare spending in the region supporting eye care and eye health, as well as acceptable compensation for a variety of ocular problems, encourage the region's major economies to adopt cutting-edge and novel treatments. Whereas Europe is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nViatris Inc.\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nAbbVie Inc.\u003cbr\u003e\nF. Hoffmann-La Roche Ltd.\u003cbr\u003e\nRegeneron Pharmaceuticals, Inc.\u003cbr\u003e\nSanten Pharmaceutical Co., Ltd.\u003cbr\u003e\nBayer AG\u003cbr\u003e\nBausch \u0026amp; Lomb Incorporated\u003cbr\u003e\nMerck KGaA\u003cbr\u003e\nNicox SA\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In May 2022, Zhaoke Ophthalmology Limited and Visus Therapeutics, Inc. partnership to commercialize BRIMOCHOL PF and Carbachol PF in Greater China, South Korea, and a few other Southeast Asian countries. Visus Therapeutics, Inc. specializes in the development of ophthalmic therapies. Both of these eye drops lack preservatives and are intended to correct presbyopia-related vision problems.\u003cbr\u003e\n? In March 2022, The European Commission has given Novartis AG clearance to market Beovu, an ophthalmic drug intended to treat diabetic macular edema-related vision loss.\u003c\/p\u003e\n\n\n\n\n\u003cp\u003eGlobal Ophthalmic Disease Therapeutics  Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Drug Class, Dosage Form, Disease Indication, Distribution Channel, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Classofferings of key players. The detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Drug Class:\u003cbr\u003e\nAnti-inflammatory\u003cbr\u003e\nAnti-invectives\u003cbr\u003e\nAnti-VEGF\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Dosage Form:\u003cbr\u003e\nSolid\u003cbr\u003e\nLiquid\u003cbr\u003e\nSemisolid\u003cbr\u003e\nBy Disease Indication:\u003cbr\u003e\nGlaucoma\u003cbr\u003e\nDry Eye Disease\u003cbr\u003e\nRetinal Disease\u003cbr\u003e\nAllergy \u0026amp; Infections\u003cbr\u003e\nOthers\u003cbr\u003e\nBy Distribution Channel:\u003cbr\u003e\nHospital Pharmacies\u003cbr\u003e\nRetail \u0026amp; Online Pharmacies\u003cbr\u003e\nBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRoLA\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nViatris Inc.\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nAbbVie Inc.\u003cbr\u003e\nF. Hoffmann-La Roche Ltd.\u003cbr\u003e\nRegeneron Pharmaceuticals, Inc.\u003cbr\u003e\nSanten Pharmaceutical Co., Ltd.\u003cbr\u003e\nBayer AG\u003cbr\u003e\nBausch \u0026amp; Lomb Incorporated\u003cbr\u003e\nMerck KGaA\u003cbr\u003e\nNicox SA\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 200 Pages \/ MCW16241322","offer_id":47657827434802,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-ophthalmic-disease-therapeutics-market-size-study-forecast-by-drug-class-anti-inflammatory-anti-invectives-anti-vegf-and-others-by-dosage-form-solid-liquid-and-semisolid-by-disease-indication-glaucoma-dry-eye-disease-retinal-disease","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}